Milk Thistle Liver Disease Meta-analysis: What the Evidence Says

Quick Answer

Milk Thistle Liver Disease Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Recent mechanistic evidence suggests that these pathways converge on mitochondrial protection and the regulation of oxidative phosphorylation, contributing to their dual hepatocellular and neuroprotective actions. [Sayyad Mahewish (2025); evidence level 4]
• Increased production of key antioxidant and detoxification enzymes and cofactors. [Sayyad Mahewish (2025); evidence level 4]
• The disease significantly impairs patients' quality of life, often manifesting as dysmenorrhea, dyspareunia, and chronic fatigue, and has been associated with comorbid inflammatory and autoimmune disorders including rheumatoid arthritis, psoriasis, and migraine. [Burdan Oliwia (2025); evidence level 4]
• Many hypotheses have been proposed to explain the development of endometriosis, and they all essentially boil down to a dysregulated hormonal balance and increased levels of pro-inflammatory cytokines. [Burdan Oliwia (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For milk thistle liver disease meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Sayyad Mahewish (2025). Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. DOI: 10.3389/fphar.2025.1711653. PMCID: PMC12695834. PMID: 41394134. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12695834/
• Burdan Oliwia (2025). Mechanistic Insights into the Anti-Inflammatory and Anti-Proliferative Effects of Selected Medicinal Plants in Endometriosis. DOI: 10.3390/ijms262210947. PMCID: PMC12652039. PMID: 41303437. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12652039/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.